Key Takeaways INSM gained after the EU approved Brinsupri for NCFB in patients 12 and older with prior exacerbations.Brinsupri cut annual exacerbations by 19.4% in the ASPEN study and met key secondary goals.Regulatory filings for Brinsupri are also underway review in the United Kingdom and Japan.Insmed (INSM) announced that the European Commission has approved Brinsupri (brensocatib) for the treatment of non-cystic fibrosis bronchiectasis (“NCFB”). Shares of the company were up 2.1% following the announcem ...